Journal of Transcatheter Interventions

FINAL CONSIDERATIONS This clinical trial supports the increasingly growing importance of using drug therapy oriented by the most updated guidelines to treat ischemic ventricular dysfunction, regardless of patients being revascularized or not. This had already been demonstrated in the ISCHEMIA trial and, mainly in analysis of subgroups of this study, which enrolled 398 patients with ejection fraction between 35% and 45%, there was a clear benefit of revascularization over OMT after a 4-year follow-up. Other considerations can only be inferred […]

Letter to: Latin American Association of Cardiac and Endovascular Surgery. Dayan et al.1 , on behalf of the Latin American Association of Cardiac and Endovascular Surgery (LACES), expressed their concerns about the development and relevance of our clinical practice guideline for the use of transcatheter aortic valve implant (TAVI) or surgical aortic valve replacement (SAVR), in patients with severe aortic stenosis living in Latin America.2 In this response, we address several points raised in their letter.1 […]

Letter to the Editor-in-Chief of the Journal of Transcatheter Interventions: Dear Dr. Beraldo de Andrade, […]

Much has been researched on the treatment of chronic coronary artery disease (CAD).– The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial had been long awaited, in the hope that it would answer many remaining questions. Our purpose is to prepare a critical analysis of this document, analyzing its methodology, its results and how it may impact the cardiologist’s clinical practice. Initially, when examining the methodology, a difference is noted between what was planned regarding […]